Because identifying and communicating with patients who are willing to participate in trials can be a significant challenge, Synexus says it is keen to adopt a streamlined process that offers consistency across multiple channels.
Synexus, a site management organization headquartered in Manchester, UK, has appointed business process management company Firstsource Solutions to review and support its strategy for communicating with patients across the United Kingdom. The aim is to create real-time responsiveness and dialogue, leading to an enhanced patient experience throughout the clinical trial process, according to the company.
Because identifying and communicating with patients who are willing to participate in trials can be a significant challenge, Synexus says it is keen to adopt a streamlined process that offers consistency across multiple channels and builds awareness and understanding of the benefits that clinical research can bring for patients, leading to better engagement.
“We selected Firstsource as our partner of choice because of the significant experience they have with major consumer brands that are highly sophisticated when it comes to adopting a multi-channel approach,” noted Sarah Beeby, VP Global Strategic Service Development at Synexus. “We hope to learn from their experiences and apply these to develop a communications strategy that will boost the awareness of clinical trials.”
Targeted messaging of engaging content across various platforms will boost understanding of the benefits of clinical trial participation, and these benefits will carry through the life of the trial by ensuring participants feel well informed and stay motivated to the end of the study, she added.
“In today’s multi-channel world, multiple touch points are becoming a business necessity rather than a ‘nice to have’, and the health sector is no exception,” said Gavin Snell, President, Customer Management, Firstsource Solutions. “Whilst Synexus has offered numerous engagement opportunities to its patients this project will take the business to the next level and really transform the patient experience.”
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.